Kamal Saini, MD

Kamal Saini, MD, executive medical director at Fortrea Inc., is a board-certified medical oncologist based in Cambridge, United Kingdom, where he also practices part-time at the Addenbrooke’s (Cambridge University) Hospital. He contributes to the scientific strategic leadership of the oncology therapeutic area at Fortrea and provides clinical and medical expertise to project teams and other Fortrea departments on clients’ drug development projects. He liaises with key opinion leaders and academic cooperative groups with regard to the design, setup, and execution of cancer trials, especially in the breast cancer subdomain. He manages a team of high-performing medical monitors who are a part of the European oncology team. He leads the Precision Medicine and Emerging Therapies Leadership Center at Fortrea, and is also our global Scientific Publications Lead (Oncology). He brings more than 15 years of experience in clinical research and development to Fortrea. He is the author or co-author of several peer-reviewed journal articles. He joined our company in 2015.

Publications

• The Evolving Landscape in Multiple Myeloma: From Risk Stratification to T Cell-Directed Advanced Therapies
• Unraveling the link between cholesterol and immune system in cancer: From biological mechanistic insights to clinical evidence. A narrative review
• CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2– early breast cancer
• Bladder Cancer, Loss of Y Chromosome, and New Opportunities for Immunotherapy
• The Convergence of Radiology and Genomics: Advancing Breast Cancer Diagnosis with Radiogenomics
• The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer
• Equitable inclusion of diverse populations in oncology clinical trials: deterrents and drivers
• Cancer Trials Ecosystem in India—Ready for Prime Time?
• Real-world comprehensive genomic and immune profiling reveals distinct age- and sex-based genomic and immune landscapes in tumors of patients with non-small cell lung cancer
• Differential impact of lipid profile according to neutrophil-to-lymphocyte ratio status in patients with advanced cancer treated with immunotherapy
• Window of opportunity trials with immune checkpoint inhibitors in triple-negative breast cancer
• Biomarkers in head and neck squamous cell carcinoma: unraveling the path to precision immunotherapy
• Case report: Single gene testing and comprehensive genomic profiling in non-small cell lung cancer—a case series of divergent results from a large reference laboratory
• Quantifying the impact of the COVID-19 pandemic on clinical trial screening rates over time in 37 countries
• Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer
• RNA Sequencing Identifies Novel NRG1 Fusions in Solid Tumors that Lack Co-Occurring Oncogenic Drivers
• Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy
• Intracellular DNA sensing by neutrophils and amplification of the innate immune response
• Recent Advances in Gynecological Malignancies: Focus on ASCO 2023
• From Incidence to Intervention: A Comprehensive Look at Breast Cancer in South Africa
• Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate?
• CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond
• Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer
• Immuno-oncology trends: preclinical models, biomarkers, and clinical development
• Manufacture of adoptive cell therapies at academic cancer centers: scientific, safety and regulatory challenges
• Role of decentralized clinical trials in cancer drug development: Results from a survey of oncologists and patients
• Determining lines of therapy in patients with solid cancers: a proposed new systematic and comprehensive framework
• Emerging issues related to COVID-19 vaccination in patients with cancer
• Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D)
• Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics
• Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis
• Effect of the COVID-19 pandemic on cancer treatment and research
• Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy
• Cancer Treatment and Research During the COVID-19 Pandemic: Experience of the First 6 Months
• Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to Arms
• Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D)